09:00

WELCOME

09:10

PLENARY SESSIONS 1

1. RIVA: Nele Kindt, Jolien Van den Dries, Katrien Janssen:
2. Science Park: Sara Landuydt: 
   Building Business on Science

10:10

BREAK

10:30

PLENARY SESSIONS 2

1. Sightera Biosciences: Hendrik Verkammen, Maxim Le Compte:
   AI powered, patient-centric solutions
2. Diana Campillo Davó:
   The search for the Holy (Grail) TCR: A crusade against cancer
3. Michaël Claessens:

PITCHES RESEARCHERS

1. Accelerate Drug Discovery with DrugVision.AI: High-Throughput Drug Screening on Patient-Derived Tumor Organoids, Christophe Deben
2. High-throughput single cell phenotypic profiling reveals selective vulnerabilities in two- and three-dimensional glioblastoma model systems, Winnok De Vos
3. Improving oral cancer surgery by intra-operative assessment of resection margins: need for objective techniques, Senada Koljenovic
4. Prediction of immune checkpoint inhibitor response in NSCLC, Inge Mertens
5. The Antwerp ATMP hub: consolidating the cell, gene and tissue engineering ecosystem, Eva Lion
6. CASUS: a fully molecular cervical cancer screening approach, based on first-void urine as an easily accessible and non-invasive source of biomarkers, Severien Van Keer
7. A novel singlet oxygen-based photoelectrochemical platform for the specific detection of nucleic acid-based cancer biomarkers, Elise Daems
8. IMPRESS: improved multiplex methylation profiling using restriction enzymes and smMIP sequencing for highly sensitive multi-cancer detection, Ken Op de Beeck

1. Galapagos: François Gonzalvez
2. Johnson & Johnson: Viggo Van Tendeloo:
   The J&J Innovation collaboration model: Advancing new healthcare solutions through partnerships

1. Novel inhibitors to inhibit the stroma-cancer cross to preventie cancer growth, Sheila Krishnadath
2. ..
3. ..
4. ..
5. ..
6. ..